ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells

Abstract

Backgroundp53 is a tumour suppressor protein that plays a key role in many steps of apoptosis, and malfunctioning of this transcription factor leads to tumorigenesis. Prognosis of many tumours also depends upon the p53 status. Most of the clinically used anticancer compounds activate p53 dependent pathway of apoptosis and hence require p53 for their mechanism of action. Further, Ras/Raf/MEK/ERK axis is an important signaling pathway activated in many cancers. Dependence of diaminothiazoles, compounds that have gained importance recently due to their anticancer and anti angiogenic activities, were tested in cancer models with varying p53 or Ras/Raf mutational status.MethodsIn this study we have used p53 mutated and knock out colon cancer cells and xenograft tumours to study the role of p53 in apoptosis mediated by diaminothiazoles. Colon cancer cell lines with varying mutational status for Ras or Raf were also used. We have also examined the toxicity and in vivo efficacy of a lead diaminothiazole 4-Amino-5-benzoyl-2-(4-methoxy phenylamino)thiazole (DAT1) in colon cancer xenografts.ResultsWe have found that DAT1 is active in both in vitro and in vivo models with nonfunctional p53. Earlier studies have shown that extrinsic pathway plays major role in DAT1 mediated apoptosis. In this study, we have found that DAT1 is causing p53 independent upregulation of the death receptor 5 by activating the Ras/Raf/MEK/ERK signaling pathway both in wild type and p53 suppressed colon cancer cells. These findings are also confirmed by the in vivo results. Further, DAT1 is more efficient to induce apoptosis in colon cancer cells with mutated Ras or Raf.ConclusionsMinimal toxicity in both acute and subacute studies along with the in vitro and in vivo efficacy of DAT1 in cancers with both wild type and nonfunctional p53 place it as a highly beneficial candidate for cancer chemotherapy. Besides, efficiency in cancer cells with mutations in the Ras oncoprotein or its downstream kinase Raf raise interest in diaminothiazole class of compounds for further follow-up.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-016-0505-7) contains supplementary material, which is available to authorized users.

Aloe-Emodin-Mediated Photodynamic Therapy Induces Apoptosis in Basal Cell Carcinoma Cells via Activation of ERK/JNK Signaling Pathway

“…At the same time, the other stated studies with similar findings do not give any clear explanation. To justify our finding of p-ERK activation upon AE-mediated PDT, we would agree with a postulation that ERK activation may depend on the cell type and the duration of phototherapy [39]. We thus report that AEmediated PDT leads to activation of p-ERK on BCC.…”

Luteolin sensitizes human liver cancer cells to TRAIL‑induced apoptosis via autophagy and JNK‑mediated death receptor 5 upregulation

“…5 and 6). Recent reports have also revealed that Akt, ERK and JNK can mediate DR upregulation (53)(54)(55). The findings of this study suggested that luteolin induced JNK activation via DR upregulation (Fig.…”

Investigation of Apoptotic Effect of Klotho Protein on Human Colorectal Cancer Cells via TRAIL Death Receptors

“…It has been reported that some clinically used drugs make cancer cells sensitive to TRAIL by increasing the protein level of TRAILR1 and TRAILR2 [39]. Previous studies have shown that DAT1, one of the diaminothiazole drugs known to have antimitotic effects on colon cancer cells (HCT-116), activates the MEK/ERK signaling pathway, increasing the expression of the TRAILR2 receptor independent of p53.…”